Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study

被引:2
|
作者
Avallone, Gianluca [1 ,2 ]
Cavallo, Francesco [2 ]
Tancredi, Annalisa [3 ]
Maronese, Carlo A. [4 ,5 ]
Bertello, Martina [6 ]
Fraghi, Alessandro [7 ]
Conforti, Claudio [8 ,9 ]
Calabrese, Giulia [10 ]
Di Nicola, Matteo R. [11 ]
Oddenino, Giorgio A. [12 ]
Gargiulo, Luigi [13 ,14 ]
Gori, Niccolo [15 ,16 ]
Loi, Camilla [17 ,18 ]
Romita, Paolo [19 ]
Piras, Viviana [20 ]
Bonzano, Laura [21 ]
Tolino, Ersilia [22 ]
Paolino, Giovanni [11 ,23 ]
Napolitano, Maddalena [24 ]
Patruno, Cataldo [25 ]
Nettis, Eustachio [26 ]
Ferreli, Caterina [27 ]
Roccuzzo, Gabriele [2 ]
Marozio, Luca [3 ]
Silvio, Martina [4 ,5 ]
Russo, Filomena [6 ]
Bettolini, Luca [7 ]
Gallo, Rosella [12 ]
Mercuri, Santo R. [11 ,23 ]
Mastorino, Luca [2 ]
Rossi, Mariateresa [7 ]
Zalaudek, Iris [8 ]
Argenziano, Giuseppe [10 ]
Trave, Ilaria [12 ]
Costanzo, Antonio [13 ,14 ]
Chiricozzi, Andrea [15 ,16 ]
Gurioli, Carlotta [17 ,18 ]
Foti, Caterina [19 ]
Potenza, Concetta [22 ]
Ferrucci, Silvia M. [4 ]
Balato, Anna [10 ]
Parodi, Aurora [12 ]
Marzano, Angelo V. [4 ,5 ]
Ortoncelli, Michela [2 ]
Ribero, Simone [2 ]
Quaglino, Pietro [2 ]
机构
[1] Univ Turin, Dept Med Sci, Sect Dermatol, Via Cherasco 23, I-10121 Turin, Italy
[2] Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy
[3] Univ Torino, St Anna Hosp, Physiopathol Reprod & IVF Unit, Obstet & Gynecol 1U,Dept Surg Sci, Turin, Italy
[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy
[5] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[6] Univ Siena, Santa Maria Alle Scotte Hosp, Dermatol Sect, Dept Med Surg & Neurol Sci, Siena, Italy
[7] Univ Brescia, Dermatol Dept, Brescia, Italy
[8] Univ Trieste, Maggiore Hosp, Dermatol Clin, Trieste, Italy
[9] Dermatol Res Hosp, IDI IRCCS, Rome, Italy
[10] Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy
[11] IRCCS Osped San Raffaele, Unit Dermatol, Milan, Italy
[12] Univ Genoa, IRCCS Osped Policlin San Martino, Dept Hlth Sci, Sect Dermatol, Genoa, Italy
[13] IRCCS Humanitas Res Hosp, Dermatol Unit, Rozzano, MI, Italy
[14] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
[15] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, UOC Dermatol, Rome, Italy
[16] Univ Cattolica Sacro Cuore, Dipartimento Med & Chirurg Traslaz, Dermatol, Rome, Italy
[17] IRCCS Azienda Osped Univ Bologna, Dermatol Unit, Bologna, Italy
[18] Univ Bologna, Dept Med & Surg Sci, Alma Mater Studiorum, Bologna, Italy
[19] Univ Bari Aldo Moro, Dept Precis & Regenerat Med & Ionian Area, Unit Dermatol, Bari, Italy
[20] Azienda Osped Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy
[21] Azienda USL IRCCS Reggio Emilia, Dermatol Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[22] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Polo Pontino, Rome, Italy
[23] Univ Vita Salute San Raffaele, Dermatol Clin, Milan, Italy
[24] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy
[25] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy
[26] Univ Bari Aldo Moro, Sch Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy
[27] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy
关键词
PLACEBO;
D O I
10.1111/jdv.19794
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundThere is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required.ObjectiveTo investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post-partum outcomes.MethodsWe performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18-49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022.ResultsWe retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3-118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2-24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug-associated risk for adverse pregnancy, congenital, neonatal or post-partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors.ConclusionsThis cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.
引用
收藏
页码:1799 / 1808
页数:10
相关论文
共 50 条
  • [31] Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
    Kuznik, Andreas
    Bego-Le-Bagousse, Gaelle
    Eckert, Laurent
    Gadkari, Abhijit
    Simpson, Eric
    Graham, Christopher N.
    Miles, LaStella
    Mastey, Vera
    Mahajan, Puneet
    Sullivan, Sean D.
    DERMATOLOGY AND THERAPY, 2017, 7 (04) : 493 - 505
  • [32] Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis
    Berdyshev, Evgeny
    Goleva, Elena
    Bissonnette, Robert
    Bronova, Irina
    Bronoff, Anna Sofia
    Richers, Brittany N.
    Garcia, Shannon
    Ramirez-Gama, Marco
    Taylor, Patricia
    Praestgaard, Amy
    Agueusop, Inoncent
    Jurvilliers, Pauline
    Boguniewicz, Mark
    Levit, Noah A.
    Rossi, Ana B.
    Zhang, Annie
    Leung, Donald Y. M.
    ALLERGY, 2022, 77 (11) : 3388 - 3397
  • [33] Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan, I
    Rubini, Norma P. M.
    Pires, Mario C.
    Rossi, Ana B.
    Zhang, Annie
    Chen, Zhen
    Levit, Noah A.
    Chao, Jingdong
    Shumel, Brad
    Bego-Le Bagousse, Gaelle
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05): : 1279 - +
  • [34] Sleep improvement with dupilumab in adults with moderate-to-severe atopic dermatitis: Results of the DUPISTAD study
    Merola, J.
    Chiou, A.
    Foley, P.
    Ardeleanu, M.
    Wu, J.
    Ozturk, Z. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [35] Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series
    Armario-Hita, J. C.
    Pereyra-Rodriguez, J.
    Silvestre, J. F.
    Ruiz-Villaverde, R.
    Valero, A.
    Izu-Belloso, R.
    Jauregui-Presa, I.
    Curto-Barredo, L.
    Figueras-Nart, I.
    Herranz-Pinto, P.
    Herraez-Herrera, L.
    Ortiz-de-Frutos, F. J.
    Martinez-Pilar, L.
    Sastre, J.
    Serra-Baldrich, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) : 1072 - 1074
  • [36] Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China
    Peng, Cong
    Cao, Qiaozhi
    Xiong, Feng
    Xu, Hui
    Li, Jie
    MEDCOMM, 2024, 5 (10):
  • [37] Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study
    Hosseini-Ashrafi, Mozhgan
    Clayton, Tim H.
    Herring, Michelle
    Herety, Nichola
    Arkwright, Peter D.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (06) : 578 - 583
  • [38] Depth and rapidity of response with abrocitinib and dupilumab in patients with moderate-to-severe atopic dermatitis in JADE COMPARE
    Lio, P.
    Boguniewicz, M.
    Alexis, A.
    Lebwohl, M.
    Reich, K.
    Pink, A.
    Kabashima, K.
    Bissonnette, R.
    Nowicki, R. J.
    Valdez, H.
    Zhang, F.
    DiBonaventura, M.
    Clibborn, C.
    Cameron, M. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E138 - E139
  • [39] COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
    Ungar, Benjamin
    Glickman, Jacob W.
    Golant, Alexandra K.
    Dubin, Celina
    Marushchak, Olga
    Gontzes, Alyssa
    Mikhaylov, Daniela
    Singer, Giselle K.
    Baum, Danielle
    Wei, Nancy
    Sanin, Antonio
    Gruenstein, Diana
    Lebwohl, Mark G.
    Pavel, Ana B.
    Guttman-Yassky, Emma
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (01): : 134 - 142
  • [40] Dupilumab treatment induces rapid clinical improvement of itch in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan I.
    Eckert, Laurent
    Ardeleanu, Marius
    Chen, Zhen
    Akinlade, Bolanle
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozi, Gianluca
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB113 - AB113